Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Chuong Le

Neuromuscular Medicine Savannah, GA Medical Doctor

NPI 1568501005 CMS profile 977421

4 E Jackson Blvd, Suite 475, Savannah, GA 31405

Open in the dashboard

General payments

$622

9 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Chuong Le of Savannah, GA is reported in the CMS Open Payments database as having received $622 across 9 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 40th percentile of Neuromuscular Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $121 1
2023 General $110 5
2022 General $123 1
2021 General $125 1
2019 General $143 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Chuong Le
  • Neuromuscular Medicine median
  • Middle half of Neuromuscular Medicine
  • National median

In program year 2025, general payments to Chuong Le were reported at $121. Among 188 Neuromuscular Medicine profiles paid that year, the median was $530 and the middle half received between $134 and $6,440.

Show as a table
Year Chuong Le Neuromuscular Medicine median Middle half National median
2019 $143 $356 $114–$4,219 $163
2020 $0 $287 $72–$5,632 $114
2021 $125 $193 $73–$1,841 $132
2022 $123 $362 $109–$2,461 $149
2023 $110 $411 $119–$3,356 $160
2024 $0 $394 $122–$5,116 $164
2025 $121 $530 $134–$6,440 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Amarin Pharma Inc. $143 1 payment
  2. Boston Scientific Corporation $125 1 payment
  3. Neurocrine Biosciences, Inc. $123 1 payment
  4. Vanda Pharmaceuticals Inc. $121 1 payment
  5. AbbVie, Inc. $110 5 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $622 9 payments
Products named General payments · program years 2019–2025
  1. Vascepa $143 1 payment
  2. GENERAL PAIN MANAGEMENT $125 1 payment
  3. INGREZZA $123 1 payment
  4. FANAPT $121 1 payment
  5. BOTOX Botox Therapeutic $28 1 payment
  6. BOTOX Facial Aesthetics $26 1 payment
  7. DUOPA $21 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 36 drugs

Part D claims

5,651

Median for Neurology: 833

Drug cost

$157,536

Median for Neurology: $202,670

Branded share of claims

12.3%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 1,782 $34,485
Carbidopa-Levodopa Carbidopa/Levodopa Brand 458 $18,466
Memantine Hcl Generic 581 $16,720
Levetiracetam Generic 390 $14,582
Carbamazepine Er Carbamazepine Brand 116 $12,977
Lacosamide Generic 28 $12,596
Baclofen Generic 738 $11,445
Donepezil Hcl Generic 342 $7,602
Sumatriptan Succinate Generic 129 $3,767
Divalproex Sodium Generic 138 $3,140

The 10 drugs with the highest cost, of 36 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 4 billing codes

Paid by Medicare

$123,480

Medicare's payments for the services billed

Medicare patients

544

Average age 73

Services billed

1,504

322 women, 222 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 46%
Arthritis 32%
Alzheimer's or dementia 30%
Osteoporosis 27%
Chronic kidney disease 23%
Ischemic heart disease 22%
Depression 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

9 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neuromuscular Medicine in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record